Allen Mangel, MD, PhD - Executive Vice President, RTI Health Solutions
Allen Mangel, MD, PhD, is a gastroenterologist and Executive Vice President of RTI-HS. Following completion of his medical training, Dr. Mangel did his internship and residency in internal medicine at Duke University Medical Center and then completed his gastroenterology fellowship also at Duke. Following completion of his formal training, he remained on the faculty in the Department of Medicine, Division of Gastroenterology, at Duke for 2 years. Dr. Mangel also has a PhD from the University of Illinois, where his research focused on control of electrical and mechanical activity in gastrointestinal smooth muscle.
After Dr. Mangel left Duke, he joined the gastroenterology clinical research department at GlaxoWellcome, where he conducted numerous clinical trials and directed product development teams. After departing GlaxoWellcome, he became Vice President of Research and Development at Salix Pharmaceuticals. He joined RTI International in 2003 and currently serves as Executive Vice President of RTI-HS.
Dr. Mangel has led or participated in numerous FDA interactions, advisory committee presentations, label negotiations, and new drug application submissions, and he has authored more than 100 publications.
Christopher R. Simmons, CPA - Senior Vice President
Chris Simmons is Senior Vice President of RTI-HS. In this role, he works closely with Allen Mangel and the heads of the research and operations groups to lead the organization. Mr. Simmons joined RTI-HS as its first full-time finance executive in 2003, and over time moved to manage the operations groups of the organization before taking his current role.
Chris is a CPA who has spent more than 30 years in financial and operational positions, with particular focus on early-stage, rapidly growing technology and biotech businesses. Mr. Simmons began his career at KPMG and moved to other public accounting firms whose focus was more on early-stage businesses. Mr. Simmons then moved into corporate finance as controller for Mitsubishi Semiconductor America, Inc., a semiconductor manufacturer. Upon leaving Mitsubishi, Mr. Simmons served 4 years as corporate controller and then vice president of finance for a start-up biotech company, Cogent Neuroscience, Inc.
Just prior to joining RTI-HS, Mr. Simmons consulted for several other early-stage biotech and high-tech businesses as leader of finance.
Dave Obringer, JD - Vice President, Contracting
Dave Obringer leads the contracting and procurement group supporting RTI-HS. He conducts legal and business review of contractual agreements and supports the review and implementation of strategic alliances and acquisitions. He conducts research and evaluation of key legal and business issues relevant to RTI-HS and works on the creation and implementation of procedures, processes, and tools for managing those issues, working with outside counsel as appropriate.
Mr. Obringer also serves as the data protection official for RTI-HS. In this role, he evaluates privacy and data protection regulations relevant to the research conducted by RTI-HS, advises staff on compliance practices and provides tools to facilitate compliance, and evaluates third-party suppliers and systems against applicable data protection requirements.
Prior to joining RTI-HS, Mr. Obringer served as the lead transactional attorney at RTI International. In that role, he provided advice and counsel on corporate-wide legal and regulatory matters, reviewed and approved contractual and legal documents for the research businesses, and provided counsel to RTI International's administrative units. He has consulted with and managed outside counsel as needed, and led a large legal/administrative team including attorneys, contract professionals, and support staff.
Lawrence N. Bell, PhD - Vice President, Business Affairs
Lawrence Bell, PhD, is the Vice President of Business Affairs for RTI-HS. He has extensive management and hands-on experience consulting for and within the pharmaceutical industry to develop people, processes, and systems related to outcomes research, drug development, and health policy. At RTI-HS he has guided a number of business and technical functions, including Business Development, Office of Quality Assurance, Health Outcomes Strategy, and Health Economics. In addition, he has been extensively involved in the pre-IND (nonclinical) development of two novel chemical entities. He has broad experience with development strategy, including bench and scale-up chemistry, drug and dosage formulation and stability, and clinical trials.
For more than 25 years, he served as a management team member for various divisions and departments of a major pharmaceutical company, establishing and shaping the direction of a number of groups, including Project Planning (tasks and their dependencies, timelines, and costs/budgets to submit INDs and NDAs), Health Economics, Health Policy Research, Clinical Data Processing and Management, and Quality Assurance.
He has published in journals, including PharmacoEconomics, Journal of Medicinal Chemistry, International Journal of Technology Assessment in Health Care, Pharmacotherapy, Epilepsia, Journal of the American Chemical Society, and Journal of Organic Chemistry. Additionally, Dr. Bell was coauthor, coordinator, and editor for Chapter 3, “Estimating Drug Development Costs,” in the report “The Economics of TB Drug Development.”